X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Torrent Pharma with Merck Ltd - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

TORRENT PHARMA vs MERCK - Comparison Results

TORRENT PHARMA    Change

Torrent Pharmaceuticals Ltd. is the flagship company of the Torrent Group set up in 1959. Based in Ahmedabad, it was promoted by Mr U.N. Mehta initially as Trinity Laboratories Ltd. and was later renamed to its current name. The company derives its r... More

MERCK 
   Change

Merck, the Indian arm of Merck KgaA (Germany), is a relatively smaller player among MNC pharma majors in the country. Merck has two business segments namely Pharmaceuticals and Chemicals. The pharmaceutical business, accounting for 68% of total sales... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    TORRENT PHARMA MERCK TORRENT PHARMA/
MERCK
 
P/E (TTM) x 39.1 50.9 76.8% View Chart
P/BV x 6.9 7.6 90.3% View Chart
Dividend Yield % 0.7 0.4 167.3%  

Financials

 TORRENT PHARMA   MERCK
EQUITY SHARE DATA
    TORRENT PHARMA
Mar-18
MERCK
Dec-17
TORRENT PHARMA/
MERCK
5-Yr Chart
Click to enlarge
High Rs1,5501,358 114.2%   
Low Rs1,144933 122.6%   
Sales per share (Unadj.) Rs354.7665.0 53.3%  
Earnings per share (Unadj.) Rs40.156.6 70.8%  
Cash flow per share (Unadj.) Rs64.272.5 88.6%  
Dividends per share (Unadj.) Rs14.0015.00 93.3%  
Dividend yield (eoy) %1.01.3 79.4%  
Book value per share (Unadj.) Rs273.1441.7 61.8%  
Shares outstanding (eoy) m169.2216.60 1,019.4%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.81.7 220.5%   
Avg P/E ratio x33.620.2 166.0%  
P/CF ratio (eoy) x21.015.8 132.7%  
Price / Book Value ratio x4.92.6 190.2%  
Dividend payout %34.926.5 131.8%   
Avg Mkt Cap Rs m227,89719,011 1,198.8%   
No. of employees `00014.71.5 952.1%   
Total wages/salary Rs m11,3531,696 669.2%   
Avg. sales/employee Rs Th4,083.07,150.0 57.1%   
Avg. wages/employee Rs Th772.31,098.7 70.3%   
Avg. net profit/employee Rs Th461.3608.2 75.8%   
INCOME DATA
Net Sales Rs m60,02111,040 543.7%  
Other income Rs m2,988240 1,246.7%   
Total revenues Rs m63,00911,279 558.6%   
Gross profit Rs m13,4931,376 980.4%  
Depreciation Rs m4,086264 1,547.7%   
Interest Rs m3,0850-   
Profit before tax Rs m9,3101,352 688.7%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0170 0.0%   
Tax Rs m2,529583 433.9%   
Profit after tax Rs m6,781939 722.1%  
Gross profit margin %22.512.5 180.3%  
Effective tax rate %27.243.1 63.0%   
Net profit margin %11.38.5 132.8%  
BALANCE SHEET DATA
Current assets Rs m52,6237,523 699.5%   
Current liabilities Rs m52,0222,253 2,309.4%   
Net working cap to sales %1.047.7 2.1%  
Current ratio x1.03.3 30.3%  
Inventory Days Days12052 229.3%  
Debtors Days Days7641 188.0%  
Net fixed assets Rs m85,0161,240 6,857.8%   
Share capital Rs m846166 509.8%   
"Free" reserves Rs m45,3767,167 633.2%   
Net worth Rs m46,2227,333 630.4%   
Long term debt Rs m41,1150-   
Total assets Rs m142,4329,912 1,436.9%  
Interest coverage x4.0NM-  
Debt to equity ratio x0.90-  
Sales to assets ratio x0.41.1 37.8%   
Return on assets %6.99.5 73.1%  
Return on equity %14.712.8 114.6%  
Return on capital %14.220.8 68.4%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m14,5801,015 1,437.0%   
Fx outflow Rs m3,6003,043 118.3%   
Net fx Rs m10,980-2,028 -541.4%   
CASH FLOW
From Operations Rs m8,942537 1,666.4%  
From Investments Rs m-47,070-476 9,882.3%  
From Financial Activity Rs m34,174-220 -15,547.7%  
Net Cashflow Rs m-3,655-160 2,291.5%  

Share Holding

Indian Promoters % 71.5 0.0 -  
Foreign collaborators % 0.0 51.8 -  
Indian inst/Mut Fund % 7.0 18.2 38.6%  
FIIs % 12.6 1.0 1,260.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 8.8 29.1 30.2%  
Shareholders   26,511 28,591 92.7%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare TORRENT PHARMA With:   BIOCON   CADILA HEALTHCARE  SUVEN LIFESCIENCES  PANACEA BIOTECH  WOCKHARDT  

Compare TORRENT PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 425 Points Higher; Banking and Energy Stocks Witness Buying(Closing)

Indian share markets witnessed buying interest during closing hours and ended their day on a positive note. Gains were largely seen in the banking sector and energy sector.

Related Views on News

MERCK LTD Announces Quarterly Results (3QFY19); Net Profit Up 31.3% (Quarterly Result Update)

Mar 5, 2019 | Updated on Mar 5, 2019

For the quarter ended December 2018, MERCK LTD has posted a net profit of Rs 135 m (up 31.3% YoY). Sales on the other hand came in at Rs 2 bn (down 32.8% YoY). Read on for a complete analysis of MERCK LTD's quarterly results.

TORRENT PHARMA Announces Quarterly Results (3QFY19); Net Profit Up 324.1% (Quarterly Result Update)

Jan 31, 2019 | Updated on Jan 31, 2019

For the quarter ended December 2018, TORRENT PHARMA has posted a net profit of Rs 2 bn (up 324.1% YoY). Sales on the other hand came in at Rs 21 bn (up 38.9% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

MERCK LTD Announces Quarterly Results (2QFY19); Net Profit Up 29.8% (Quarterly Result Update)

Nov 5, 2018 | Updated on Nov 5, 2018

For the quarter ended September 2018, MERCK LTD has posted a net profit of Rs 411 m (up 29.8% YoY). Sales on the other hand came in at Rs 2 bn (down 27.7% YoY). Read on for a complete analysis of MERCK LTD's quarterly results.

TORRENT PHARMA Announces Quarterly Results (2QFY19); Net Profit Down 12.3% (Quarterly Result Update)

Nov 5, 2018 | Updated on Nov 5, 2018

For the quarter ended September 2018, TORRENT PHARMA has posted a net profit of Rs 2 bn (down 12.3% YoY). Sales on the other hand came in at Rs 19 bn (up 32.5% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

MERCK LTD Announces Quarterly Results (1QFY19); Net Profit Up 63.1% (Quarterly Result Update)

Aug 8, 2018 | Updated on Aug 8, 2018

For the quarter ended June 2018, MERCK LTD has posted a net profit of Rs 328 m (up 63.1% YoY). Sales on the other hand came in at Rs 2 bn (down 17.1% YoY). Read on for a complete analysis of MERCK LTD's quarterly results.

More Views on News

Most Popular

My Top 3 Defence Stocks to Buy Now(The 5 Minute Wrapup)

Mar 19, 2019

The urgency to privatise India's defence sector to make India self-reliant was never as strong as it is today.

This Small Cap Stock Could Offer Triple Digit Gains from its Current Price(Profit Hunter)

Mar 19, 2019

If you are still waiting for signals, remember, there is no correct timing, only right time to Buy stocks. For select small caps, that time is now.

5 Fundamentally Strong Stocks to Pick for Trading Today(Profit Hunter)

Mar 15, 2019

5 fundamentally strong stocks one could buy to trade in this market right now. Make sure you grab the chance this strongly rallying market offers.

Elections Don't Matter!(The Honest Truth)

Mar 13, 2019

Ajit Dayal shows us why from the point of view of the Indian economy, elections don't matter.

Two Growth Stocks that Doubled in a Little Over 12 Months!(The 5 Minute Wrapup)

Mar 13, 2019

The elements that fueled profit growth for these two companies led to a surge in their stock prices.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

TORRENT PHARMA SHARE PRICE


Mar 26, 2019 (Close)

TRACK TORRENT PHARMA

  • Track your investment in TORRENT PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON TORRENT PHARMA

TORRENT PHARMA - FDC LTD. COMPARISON

COMPARE TORRENT PHARMA WITH

MARKET STATS